Joel Gelfand, MD, MSCE, discussed the role of GLP-1 agonists in addressing the metabolic comorbidities of psoriatic disease at Fall Clinical 2026. At Fall Clinical 2026, Todd Schlesinger, MD, ...

On this episode of Don’t Be Rash, host Andrew C. Krakowski, MD, welcomes Lawrence Eichenfield, MD, pediatric dermatologist, to discuss topical corticosteroid potency, dosing, and where they fit ...

Across social media, castor oil is frequently promoted as a natural solution for thinning hair, sparse eyebrows, and slow hair growth. Users massage the thick oil directly into th ...

Join host Cynthia Trickett, MPAS, PA-C, for a video podcast on hidradenitis suppurativa (HS), joined by Leigh Ann Pansch, MSN, FNP-BC, DCNP; Buchi Neita, PA-C, MCMSc; and Victor Czerkasij, DCNP, FNP-C ...

Christopher Bunick, MD, PhD, reviews data on investigational atopic dermatitis agents presented at EADV 2026 and biomarker findings for upadacitinib. Falk G. Bechara, MD, discusses long-term tunnel ...

Gelfand described psoriasis as an inflammatory metabolic disease. Among inflammatory diseases of medicine, he said psoriasis has by far the closest association with obesity. Obesity makes psoriasis ...

A methodical up-titration schedule and clear expectations help patients reach the point where advanced therapy is appropriate. With no approved CIndU medication, clinicians are extrapolating from CSU.

Krakowski, MD, welcomes Lawrence Eichenfield, MD, pediatric dermatologist, to discuss topical corticosteroid potency, dosing, and where they fit alongside nonsteroidal agents. Lawrence Eichenfield, MD ...

The US Food and Drug Administration (FDA) has approved pritelivir (HOVILPRI; Asahi Kasei Therapeutics) 100-mg tablets for the ...

Christopher Bunick, MD, PhD, reviews data on investigational atopic dermatitis agents presented at EADV 2026 and biomarker ...